HYTN Innovations and 4C Labs Partner on Cannabis Production
HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) has entered into a new partnership with 4C Labs, a UK-based leader in the cannabis pharmaceutical space. Together, the companies plan to produce, package, and distribute cannabis products in bulk, with the goal of increasing access in the UK and, over time, in additional international markets.
What the Agreement Covers
The collaboration is built on HYTN’s advanced manufacturing platform and its Good Manufacturing Practice (GMP) certification from Health Canada. HYTN also holds a PIC/S endorsement through Australia’s Therapeutic Goods Administration (TGA), a combination that supports consistent, high-quality production of cannabis-derived compounds. On the other side of the partnership, 4C Labs brings an established presence and licensing in the UK. Together, the teams expect to launch new cannabis products and streamline the production of existing ones—pairing secure procurement with disciplined, audited manufacturing.
What Leaders Are Saying
“This collaboration validates the ongoing regulatory work HYTN has been undertaking,” said Elliot McKerr, Chief Executive Officer of HYTN. He underscored how 4C Labs’ procurement experience fits with HYTN’s tightly controlled processes, noting that the partnership reflects HYTN’s push to grow internationally while deepening its pharmaceutical-grade production.
Greg Dobbin, CEO of 4C Labs, echoed that view: “Partnering with HYTN gives us a competitive edge. Their close proximity to superior Canadian cannabis flowers and strict adherence to GMP standards allows us to supply top-notch products to our customers at competitive prices.”
Where This Could Expand
Although the initial focus is the UK, both companies see meaningful opportunities in Germany and Australia. Germany’s medical cannabis market is positioned for substantial growth and is currently valued at around CAD $2 billion. Australia’s market has also been expanding, surpassing AUD $200 million as of last year. In both places, demand for GMP-certified production is rising. This partnership aims to meet that demand by combining reliable sourcing with rigorously managed, compliant manufacturing.
About HYTN Innovations Inc.
HYTN Innovations Inc. develops, formulates, and manufactures psychoactive and psychotropic compounds, with a particular focus on those derived from cannabis and psilocybin. The company concentrates on regulated markets, seeking out clear opportunities and moving products from concept to compliant, scalable production.
About 4C LABS Ltd.
4C Labs, headquartered in Canada, is building a tightly controlled supply and distribution network for premium medical cannabis products across the UK, the EU, and other global markets. The company supports launches within regulated frameworks and invests in research and development aimed at therapeutic applications.
What Good Manufacturing Practice (GMP) Means
Good Manufacturing Practice sets out the rules for how products are made and tested, covering everything from procedures and equipment to documentation and quality assurance. GMP compliance is mandatory in many countries and helps ensure products are consistent, traceable, and safe for patients.
About the Pharmaceutical Inspection Co-operation Scheme (PIC/S)
The Pharmaceutical Inspection Convention/Co-operation Scheme (PIC/S) brings together 56 member countries to align their GMP standards and inspections. This harmonization supports safer medicines for humans and animals and makes cross-border pharmaceutical trade more predictable and efficient.
Frequently Asked Questions
What’s the main goal of the HYTN and 4C Labs partnership?
The partnership is designed to produce, package, and distribute cannabis products at scale, starting in the UK and positioning both companies to serve additional regulated markets as demand grows.
Why does HYTN’s GMP status matter here?
HYTN holds GMP certification from Health Canada and a PIC/S endorsement via Australia’s TGA. That combination signals tightly controlled, audited processes—key for consistent quality, regulatory compliance, and market access.
Which markets are in focus beyond the UK?
Germany and Australia are identified as priority opportunities. Germany’s medical cannabis market is valued at about CAD $2 billion, while Australia’s surpassed AUD $200 million last year.
Who’s leading this collaboration?
Elliot McKerr, HYTN’s CEO, and Greg Dobbin, CEO of 4C Labs, are the executives publicly outlining the partnership’s aims and fit—procurement strength paired with GMP-grade manufacturing.
What products are expected under the deal?
The companies plan to introduce new cannabis products and to co-manufacture existing ones, focusing on efficiency, quality, and reliable supply in regulated markets.
